EPA Orders CHS Inc. in Minnesota to Stop Selling the Cancelled Pesticide Engenia

Nov 16, 2021

The U.S. Environmental Protection Agency (EPA) has issued a “stop sale” order to CHS Inc., headquartered in Inver Grove Heights, Minnesota, to immediately stop the sale or use of the cancelled pesticide Engenia in violation of the Federal Insecticide, Fungicide, and Rodenticide Act.

EPA issued a final cancellation order in June 2020 for three dicamba-based pesticides, including Engenia (EPA Reg. No. 7969-345), which prohibited the sale or use of such pesticides after July 31, 2020. In September 2021, the Minnesota Department of Agriculture documented the sale of Engenia at a CHS store in Herman, Minnesota.

Pesticides must be evaluated through EPA’s registration process to ensure that the products perform as intended prior to their distribution or sale. EPA issued the order in June 2020 cancelling the registration of Engenia and two other dicamba-based pesticides following a decision by the Ninth Circuit of the U.S. Court of Appeals vacating those registrations. Dicamba is an agricultural herbicide used to control weeds when applied to soybeans and other crops.

Source : epa.gov

Video: Finding a Balance of Innovation and Regulation - Dr. Peter Facchini

Regulations help markets and industry exist on level playing fields, keeping consumers safe and innovation from going too far. However, incredibly strict regulations can stunt innovation and cause entire industries to wither away. Dr. Peter James Facchini brings his perspective on how existing regulations have slowed the advancement of medical developments within Canada. Given the international concern of opium poppy’s illicit potential, Health Canada must abide by this global policy. But with modern technology pushing the development of many pharmaceuticals to being grown via fermentation, is it time to reconsider the rules?

Dr. Peter James Facchini leads research into the metabolic biochemistry in opium poppy at the University of Calgary. For more than 30 years, his work has contributed to the increased availability of benzylisoquinoline alkaloid biosynthetic genes to assist in the creation of morphine for pharmaceutical use. Dr. Facchini completed his B.Sc. and Ph.D. in Biological Sciences at the University of Toronto before completing Postdoctoral Fellowships in Biochemistry at the University of Kentucky in 1992 & Université de Montréal in 1995.